Last reviewed · How we verify
TAI-GPC3-CART cells
At a glance
| Generic name | TAI-GPC3-CART cells |
|---|---|
| Also known as | Gene modified patient T cells |
| Sponsor | Shanghai GeneChem Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of GPC3 Redirected Autologous T Cells for Advanced HCC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAI-GPC3-CART cells CI brief — competitive landscape report
- TAI-GPC3-CART cells updates RSS · CI watch RSS
- Shanghai GeneChem Co., Ltd. portfolio CI